Blog

    Here at McAllister Garfield, we get questions from hemp growers about the opportunities for hemp other than CBD. There are over 25,000 uses for hemp, and CBD is just one. Some of its more industrial uses include textiles, such as clothing, construction materials, food and animal bedding, just to name a few. There […]

One question that we get a lot about industrial hemp and CBD products is how to navigate the requirements of The Food and Drug Administration. One area where you can definitely get into trouble with the FDA is by making health claims about a CBD product on your label. The FDA has sent warning letters […]

This past Monday, the FDA approved Epidiolex, a marijuana derived CBD medication produced by GW Pharmaceuticals. Epidiolex – an oral solution for the treatment of certain forms of epilepsy – is the first FDA-approved drug that contains a purified derivative from marijuana. In approving Epidiolex, the FDA confirms that marijuana has medical benefits and applications, […]

This past legislative session, the Colorado General Assembly passed numerous bills related to cannabis and hemp. The following list highlights key points from a few bills that are of practical significance to operators. Please note the MED will conduct a rulemaking in the fall to implement many of these new laws and the following summary is just the highlights of each bill […]

One question that we get a lot about CBD and hemp is how to navigate FDA labeling requirements. This is a confusing topic because the FDA hasn’t provided any clear guidance about what is allowed. They’ve only posted some opinions about what is not allowed. The one thing to really avoid in this area is […]

    There is a lot of opportunity in the hemp field and there’s a lot of activity in the space as well. CBD and hemp are derived from the cannabis plant, yet are not psychoactive. They have less than 3/10ths of a percent THC. The federal government has passed some laws that protect CBD […]

Public company ownership in the cannabis industry has become a very important topic of late. In most of the country it is difficult, if not impossible, for public companies to have some sort of ownership stake in a cannabis business, or for a cannabis business to be publicly listed at all. The SEC has allowed […]

The U.S. Drug Enforcement Administration (“DEA”) stated in an internal directive last week that it lacks authority over hemp products that come from the parts of the cannabis plant exempted by the federal Controlled Substances Act (“CSA”). The directive acknowledges that hemp products containing “materials that are made from the cannabis plant and which fall […]

Private equity has been trying to invest in the cannabis industry for some time, but has found some difficulties doing so. In particular because of the structure of private equity. most equity is structured with a handful of general partners. Then dozens if not hundreds of limited partners who hand over their investment to a […]

Mergers and acquisitions in any industry are difficult, but in the cannabis industry, they’re even more so. There are a number of things in mergers and acquisitions that business, buyers, and sellers need to be aware of that they aren’t typically aware of in other industries. Due diligence is important prior to a cannabis transaction. […]

McAllister Garfield, P.C. constantly tracks developments in the California cannabis market to provide our clients with the most up-to-date information that impacts their California cannabis businesses. As such, we have two important updates for California operators: First, if you received your state temporary license on or near January 1, 2018, then your annual application is […]